Radius Health (NASDAQ:RDUS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday, January 8th.
According to Zacks, “Radius received a major boost with the approval of Tymlos for the treatment of postmenopausal women with high risk osteoporosis for fracture. Although the osteoporosis market has a great potential as approximately 1.4 million postmenopausal women in the United States experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's Forteo and Amgen’s Prolia. Further, the company suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues to its MAA for Eladynos in Europe. The CHMP will issue a third Day-180 List of Outstanding Issues in its regulatory review of abaloparatide-SC. While Radius' efforts in developing its pipeline are encouraging, we note that most of its candidates are in their early or mid stages of development. The company’ shares have underperformed the industry in the last twelve months.”
Other research analysts also recently issued research reports about the company. Maxim Group restated a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $45.00 price target on shares of Radius Health in a report on Friday, October 6th. BidaskClub raised Radius Health from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 27th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $58.00 price target on shares of Radius Health in a report on Friday, November 3rd. Finally, Jefferies Group lowered their price target on Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $48.00.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The company had revenue of $13.50 million during the quarter, compared to analyst estimates of $6.90 million. During the same period in the prior year, the firm earned ($1.07) earnings per share. sell-side analysts expect that Radius Health will post -5.57 earnings per share for the current fiscal year.
In other Radius Health news, insider Jesper Hoiland purchased 6,800 shares of the firm’s stock in a transaction dated Tuesday, November 7th. The stock was purchased at an average price of $29.04 per share, for a total transaction of $197,472.00. Following the completion of the purchase, the insider now directly owns 12,900 shares of the company’s stock, valued at $374,616. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Brent Hatzis-Schoch acquired 1,778 shares of Radius Health stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average price of $28.09 per share, with a total value of $49,944.02. Following the transaction, the vice president now owns 2,278 shares of the company’s stock, valued at approximately $63,989.02. The disclosure for this purchase can be found here. Insiders have purchased 158,578 shares of company stock worth $4,659,916 over the last 90 days. 15.00% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in RDUS. Russell Investments Group Ltd. boosted its stake in shares of Radius Health by 144.2% in the second quarter. Russell Investments Group Ltd. now owns 12,562 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 7,417 shares during the period. Sei Investments Co. boosted its stake in Radius Health by 27.7% during the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 690 shares during the last quarter. Rhumbline Advisers boosted its stake in Radius Health by 9.7% during the second quarter. Rhumbline Advisers now owns 42,480 shares of the biopharmaceutical company’s stock valued at $1,921,000 after buying an additional 3,740 shares during the last quarter. SG Americas Securities LLC boosted its stake in Radius Health by 22.9% during the second quarter. SG Americas Securities LLC now owns 8,936 shares of the biopharmaceutical company’s stock valued at $404,000 after buying an additional 1,664 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Radius Health by 19.3% during the second quarter. Bank of New York Mellon Corp now owns 529,865 shares of the biopharmaceutical company’s stock valued at $23,965,000 after purchasing an additional 85,816 shares during the period.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.